Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

Trial Profile

Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

Suspended
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Basiliximab (Primary) ; Antithymocyte globulin
  • Indications Liver-kidney transplant rejection
  • Focus Pharmacodynamics
  • Acronyms TReg Kidney
  • Most Recent Events

    • 13 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top